다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
The Cochrane database of systematic reviews, 2015 no.4, 2015년, pp. -
Adelufosi, Adegoke Oloruntoba (Northern Regional Health Authority) , Abayomi, Olukayode (Community Mental Health Program) , Ojo, Tunde Massey-Ferguson (867 Thompson Drive South Thompson Manitoba Canada)
AI-Helper
Tardive dyskinesia is a chronic and disabling abnormal movement disorder affecting the muscles of the face, neck, tongue and the limbs. It is a common side effect of long-term antipsychotic medication use in individuals with schizophrenia and other related psychotic disorders. While there are no kno...
Lerner Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study American Journal of Psychiatry 2001 10.1176/appi.ajp.158.9.1511 158 9 1511
Lerner Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study Journal of Clinical Psychiatry 2007 10.4088/JCP.v68n1103 68 11 1648
Miodownik Vitamin B6 ad-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders Harefuah 2003 142 8-9 592-6, 647
Greenberg WM A 12-week, double-blind, augmentation study of the effects of folic acid, B-12, and pyridoxine in lowering homocysteine levels and treating psychopathology and cognitive deficits in schizophrenia Stanley Foundation Research Programs 2003
10.1016/S0924-977X(99)80579-3 Lerner V Miodownik C Kaptsan A Cohen H Loewental U Kotler M Double-blind evaluation of Vitamin B6 vs Placebo in treatment of tardive dyskinesia European Neuropsychopharmacology 1999 S369
Lerner V Cohen H A double-blind, randomised, placebo-controlled, crossover study of the effects of vitamin B6 in 50 in-patients with tardive dyskinesia Stanley Foundation Research Institute 2002
Lerner Vitamin B-sub-6. The experience in treating psychotic symptoms and psychotropic drug-indced movement disorders Psychology and Schizophrenia 2007 105
Lerner V Vitamin B6 for tardive movement disorder Stanley Foundation Research Programs 2009
NCT00202280 Efficacy of treating first episode psychosis with folic acid, vitamin B12 and B6 in addition to antipsychotic medication http://www.clinicaltrials.gov./ct2/show/NCT00202280?term=NCT00202280&rank=1
Venegas Pyridoxine for drug induced dyskinesia. A placebo- controlled randomised cross-over trial Revista Chilena de Neuropsiquiatrica 2006 44 1 9
Xiao The effect of huangqi injection in the treatment of tardive neuropathy caused by acute organophosphorus insecticide poisoning Herald of Medicine 2002 21 9 558
NCT00917293 Safety and efficacy of avastrem (pyridoxal 5' -phosphate) in the treatment of tardive dyskinesia http://www.clinicaltrials.gov 2009
Adler Long-term treatment effects of vitamin E for tardive dyskinesia Biological Psychiatry 1998 10.1016/S0006-3223(97)00027-9 43 868
Altman Detecting skewness from summary information BMJ 1996 10.1136/bmj.313.7066.1200 313 1200
American Psychiatric Association Tardive dyskinesia: a task force report of the American Psychiatric Association Washington DC 1992
Ascher-Svanum Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study Journal of Clinical Psychiatry 2008 10.4088/JCP.v69n1008 69 10 1580
Ayehu Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders BMC Psychiatry 2014 10.1186/s12888-014-0280-1 14 280
Barnes The side-effects of antipsychotic drugs Antipsychotic Drugs and their Side-effects I 1993 10.1016/B978-0-12-079035-7.50021-X
Bassitt Clozapine efficacy in tardive dyskinesia in schizophrenic patients European Archives Psychiatry and Clinical Neuroscience 1998 10.1007/s004060050039 248 4 209
Boissel The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use Therapie 1999 54 4 405
Browne Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia Acta Psychiatrica Scandinavica 1996 10.1111/j.1600-0447.1996.tb09835.x 94 118
Caroff Treatment of tardive dyskinesia with donepezil: A pilot study Journal of Clinical Psychiatry 2001 10.4088/JCP.v62n1004 62 10 772
Casey Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia Schizophrenia 1995 546-65
Chakos Incidence and correlates of tardive dyskinesia in first episode of schizophrenia Archives of General Psychiatry 1996 10.1001/archpsyc.1996.01830040049009 53 313-9
Chouinard Manual for the Extrapyramidal Symptom Rating Scale (ESRS) Schizophrenia Research 2005 10.1016/j.schres.2005.02.013 76 2-3 247
Correll Tardive dyskinesia and new antipsychotics Current Opinion in Psychiatry 2008 10.1097/YCO.0b013e3282f53132 21 12 151
Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000
Elbourne Meta-analyses involving cross-over trials: methodological issues International Journal of Epidemiology 2002 10.1093/ije/31.1.140 31 1 140
Fay-McCarthy The effect of nifedipine on tardive dyskinesia: a double blind study in eighteen patients Schizophrenia Research 1997 10.1016/S0920-9964(97)82782-X 24 1-2 271
Fenton Prevalence of spontaneous dyskinesia in schizophrenia Journal of Clinical Psychiatry 2000 61 Suppl 4 10
Fleiss JL The crossover study. The design and analysis of clinical experiments Chichester: John Wiley & Sons 1984
Higgins Measuring inconsistency in meta-analyses BMJ 2003 10.1136/bmj.327.7414.557 327 557
Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
10.1089/acm.2014.5209.abstract Hoenders R Bartels-Velthuis A Vollbehr N Bruggeman R Knechtering R de Jong J Natural medicines in schizophrenia: A systematic review Journal of Alternative and Complementary Medicine 2014 A79 80
Hutton Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials British Journal of Haematology 2009 10.1111/j.1365-2141.2009.07707.x 146 1 27
Kane Integrating incidence and prevalence of tardive dyskinesia Psychopharmacology Bulletin 1986 22 254-8
Kay The positive and negative syndrome scale (PANSS) forschizophrenia Schizophrenia Bulletin 1987 10.1093/schbul/13.2.261 13 261
Leung Tardive dyskinesia in Chinese inpatients with chronic schizophrenia Progress in Neuropharmacology and Biological Psychiatry 2003 10.1016/S0278-5846(03)00171-4 27 6 1029
Lopez-Munoz History of the discovery and clinical introduction of chlorpromazine Annals of Clinical Psychiatry 2005 10.1080/10401230591002002 17 3 113
Marshall Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia British Journal of Psychiatry 2000 10.1192/bjp.176.3.249 176 249
McGrath Vitamin E for neuroleptic-induced tardive dyskinesia Cochrane Database of Systematic Reviews 2001 4 10.1002/14651858.CD000209
Miodownik Pyridoxal plasma level in schizophrenic and schizoaffective patients with and without tardive dyskinesia Clinical Neuropharmacology 2008 10.1097/WNF.0b013e3181506623 31 197
Moher The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials JAMA 2001 10.1001/jama.285.15.1987 285 1987
Nasrallah Focus on lower risk of tardive dyskinesia with atypical antipsychotics Annals of Clinical Psychiatry 2006 10.1080/10401230500464737 18 1 57
Nelson Melatonin for the treatment of tardive dyskinesia Annals of Pharmacotherapy 2003 10.1345/aph.1C460 37 1128
Niehaus Predictors of abnormal involuntary movement in an African schizophrenia population Journal of Neuropsychiatry and Clinical Neurosciences 2008 10.1176/jnp.2008.20.3.317 20 317
Sachdev Depression-dependent exacerbation of tardive dyskinesia British Journal of Psychiatry 1989 10.1192/bjp.155.2.253 155 253
Schaumburg Sensory neuropathy from pyridoxine abuse - A new megavitamin syndrome New England Journal of Medicine 1983 10.1056/NEJM198308253090801 309 445
Schünemann Chapter 12: Interpreting results and drawing conclusions Cochrane Handbook for Systematic Reviews of Interventions 2008 10.1002/9780470712184.ch12 359
Soares-Weiser Calcium channel blockers for neuroleptic-induced tardive dyskinesia Cochrane Database of Systematic Reviews 2004 1 10.1002/14651858.CD000206.pub2
Tammenmaa Cholinergic medication for neuroleptic-induced tardive dyskinesia Cochrane Database of Systematic Reviews 2002 3 10.1002/14651858.CD000207
Tenback Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study Comprehensive Psychiatry 2007 10.1016/j.comppsych.2007.05.003 48 5 436
Teo Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis Movement Disorders 2012 10.1002/mds.25107 27 1205
Waddington Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality Archives of General Psychiatry 1987 10.1001/archpsyc.1987.01800220077011 44 10 907
Woerner Diabetes and development of tardive dyskinesia American Journal of Psychiatry 1993 10.1176/ajp.150.6.966 150 966
Xia Loss to outcomes stakeholder survey: the LOSS study Psychiatric Bulletin 2009 10.1192/pb.bp.108.021949 33 7 254
Yassa Gender differences in tardive dyskinesia: a critical review of the literature Schizophrenia Bulletin 1992 10.1093/schbul/18.4.701 18 701
Zhang The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial Journal of Clinical Psychopharmacology 2004 10.1097/01.jcp.0000104912.75206.2b 24 83
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.